Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Bortenat Bortezomib 2mg Injection:
Bortenat Bortezomib 2mg Injection is a potent therapeutic agent specifically designed for the management of multiple myeloma and select lymphomas. This innovative treatment option is pivotal in modern oncology, providing effective solutions for patients battling these malignancies.
Uses of Bortenat Bortezomib 2mg Injection:
Bortenat Injection is indicated for:
Treatment of multiple myeloma in newly diagnosed and relapsed patients
Management of refractory or relapsed mantle cell lymphoma
Part of combination chemotherapy regimens for enhanced efficacy
Benefits of Bortenat Bortezomib 2mg Injection:
Effective in reducing tumor burden and promoting remission
Administered via injection for direct delivery into the bloodstream
Supports improved survival rates and quality of life for patients
Integral part of comprehensive cancer treatment strategies
Mechanism of Action of Bortenat Bortezomib 2mg Injection:
Bortezomib, the active ingredient in Bortenat, is a selective proteasome inhibitor that blocks the proteasome's function, leading to the accumulation of pro-apoptotic factors and the degradation of anti-apoptotic proteins in cancer cells. This action induces apoptosis and halts the proliferation of malignant cells, making Bortenat a crucial tool in oncology.